Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: A case-control study on survival in patients with two year follow-up

Anna Fagotti, Barbara Costantini, Marco Petrillo, Giuseppe Vizzielli, Francesco Fanfani, Pasquale Alessandro Margariti, Luigi Carlo Turco, Elisa Piovano, Giovanni Scambia

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: To compare survival data in platinum-sensitive recurrent ovarian cancer patients submitted to secondary cytoreduction (SCR) plus hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC) (Cases) and a similar group of women not experiencing HIPEC (Controls). Methods: Case-control study, matching 30 Cases with 37 Controls, with at least 24 months of follow-up. Results: Groups were comparable for all characteristics, except for a higher proportion of patients with single-nodule relapses is the Controls (19 vs. 6; p = 0.011). Median follow-up time was 46 months in the Cases and 36 months in the Controls. Twenty patients (66.6%) experienced secondary recurrence in the Cases and 37 women (100%) in the Controls (p = 0.001). Moreover, 7 (23.3%) and 23 (62.2%) patients died of disease in the Cases and Controls respectively (p = 0.003). The duration of secondary response was 26 months in the Cases and 15 months in the Controls (p = 0.004). Conclusions: The combination of SCR and HIPEC seems to improve survival rate in patients suffering from platinum-sensitive EOC recurrence with respect to no-HIPEC treatments. This result further supports the need of a randomized trial.

Original languageEnglish
Pages (from-to)502-505
Number of pages4
JournalGynecologic Oncology
Volume127
Issue number3
DOIs
Publication statusPublished - Dec 2012

Keywords

  • Case-control
  • HIPEC
  • Ovarian cancer
  • Platinum-sensitive
  • Recurrence

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Fingerprint Dive into the research topics of 'Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: A case-control study on survival in patients with two year follow-up'. Together they form a unique fingerprint.

Cite this